Nous reptes i noves oportunitats de gestió dels medicaments a l'Institut Català d'Oncologia (ICO): la cerca de la col.laboració pública-privada en l'entorn del medicament

A Catalunya es diagnostiquen cada any 33.700 nous casos de càncer (20.000 homes i 13.600 dones). Un de cada dos homes i una de cada tres dones desenvoluparan càncer al llarg de la seva vida. La mortalitat per càncer disminueix a Catalunya significativament des de 1993. ..

Additional complexity on human chromosome 15q: identification of a set of newly recognized duplicons (LCR15) on 15q11-q13, 15q24, and 15q26

Several cytogenetic alterations affect the distal part of the long arm of human chromosome 15, including recurrent rearrangements between 12p13 and 15q25, which cause congenital Fibrosarcoma [CFS). We present here the construction of a BAC/PAC contig map that spans 2 Mb from the neurotrophin-3 receptor (NTRK3] gene region on 15q25.3 to the proximal end of the Bloom's syndrome region on 15q26.1, and the identification of a set of new chromosome 15 duplicons. The contig reveals the existence of several regions of sequence similarity with other chromosomes [6q, 7p, and 12p) and with other 15q cytogenetic bands (15q11-q13 and 15q24). One region of similarity maps on 15q11-q13, close to the Prader-Willi/Angelman syndromes (PWS/AS) imprinting center. The 12p similar sequence maps on 12p13, at a distance to the ets variant 6 [ETV6) gene that is equivalent on 15q26.1 to the distance to the NTRK3 gene. These two genes are the targets of the CFS recurrent translocations, suggesting that misalignments between these two chromosomes regions could facilitate recombination. The most striking similarity identified is based on a low copy repeat sequence, mainly present on human chromosome 15 (LCR15), which could be considered a newly recognized duplicon. At least 10 copies of this duplicon are present on chromosome 15, mainly on 15q24 and 15q26. One copy is located close to a HERC2 sequence on the distal end of the PWS/AS region, three around the lysyl oxidase like [LOXl) gene on 15q24, and three on 15q26, one of which close to the IQ motif containing GTPase-activating protein I (IQGAPI) gene on 35q26.1. These LCR15 span between 13 and 22 kb and contain high identities with the golgin-like protein (GIP) and the SH3 domain-containing protein [SH3P18) gene sequences and have the characteristics of duplicons. Because duplicons flank chromosome regions that are rearranged in human genomic disorders, the LCR15 described here could represent new elements of rearrangements affecting different regions of human chromosome 15q

CD84 leukocyte antigen is a new member of the Ig superfamily

Producción CientíficacDNA isolated from a human B-cell line Raji library was ana- (CD48 and HumLy9) have been mapped. CD84 monoclonal lyzed and shown to encode the full-length cDNA sequence antibodies (MoAbs) were shown to react with cells transof a novel cell-surface glycoprotein, initially termed HLy9-b. fected with the cloned cDNA. These MoAbs were further The predicted mature 307-amino acid protein was composed used to show that CD84 is expressed as a single chain cellof two extracellular Ig-like domains, a hydrophobic trans- surface glycoprotein of Mr 64,000 to 82,000, which was membrane region, and an 83-amino acid cytoplasmic do- highly glycosylated. CD84 had a unique pattern of expresmain. The extracellular Ig-like domains presented structural sion, being found predominantly on lymphocytes and monoand sequence homology with a group of members of the Ig cytes. Thus, the glycoprotein HLy9-b is recognized by MoAbs superfamily that included CD2, CD48, CD58, and Ly9. North- previously clustered as CD84 and represents a newly identiern blot analysis showed that the expression of HLy9-b was fied member of the Ig superfamily that may play a significant predominantly restricted to hematopoietic tissues. Chromo- role in leukocyte activation

Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a resensitizing agent

[Purpose] To investigate the genetic basis of cisplatin resistance as efficacy of cisplatin-based chemotherapy in the treatment of distinct malignancies is often hampered by intrinsic or acquired drug resistance of tumor cells.[Experimental Design] We produced 14 orthoxenograft transplanting human nonseminomatous testicular germ cell tumors (TGCT) in mice, keeping the primary tumor features in terms of genotype, phenotype, and sensitivity to cisplatin. Chromosomal and genetic alterations were evaluated in matched cisplatin-sensitive and their counterpart orthoxenografts that developed resistance to cisplatin in nude mice.[Results] Comparative genomic hybridization analyses of four matched orthoxenografts identified recurrent chromosomal rearrangements across cisplatin-resistant tumors in three of them, showing gains at 9q32-q33.1 region. We found a clinical correlation between the presence of 9q32-q33.1 gains in cisplatin-refractory patients and poorer overall survival (OS) in metastatic germ cell tumors. We studied the expression profile of the 60 genes located at that genomic region. POLE3 and AKNA were the only two genes deregulated in resistant tumors harboring the 9q32-q33.1 gain. Moreover, other four genes (GCS, ZNF883, CTR1, and FLJ31713) were deregulated in all five resistant tumors independently of the 9q32-q33.1 amplification. RT-PCRs in tumors and functional analyses in Caenorhabditis elegans (C. elegans) indicate that the influence of 9q32-q33.1 genes in cisplatin resistance can be driven by either up- or downregulation. We focused on glucosylceramide synthase (GCS) to demonstrate that the GCS inhibitor DL-threo-PDMP resensitizes cisplatin-resistant germline-derived orthoxenografts to cisplatin[Conclusions] Orthoxenografts can be used preclinically not only to test the efficiency of drugs but also to identify prognosis markers and gene alterations acting as drivers of the acquired cisplatin resistance.Several authors are grateful recipients of predoctoral fellowships: J.M. Piulats from the AECC and F.J. García-Rodríguez from the Instituto de Salud Carlos III (ISCIII). This study was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2002-02265 and FIS: BFU2007-67123; PI10-0222, PI13-01339, and PI16/01898, to A. Villanueva; PI15-00895, to J. Ceron; SAF2013-46063R, to F. Vi nals; PI030264, to ~ X. García-del-Muro), Fundacio La Marat o TV3 (051430, to F. Vi nals and X. ~ García-del-Muro), Generalitat de Catalunya (2014SGR364, to A. Villanueva and F. Vinals; FIS09/0059, to A. Morales), cofunded by FEDER funds/ ~ European Regional Development Fund (ERDF) — a way to Build Europe. A. Villanueva received a BAE11/00073 grant. We thank the staff of the Animal Core Facility of IDIBELL for mouse care and maintenance.Peer reviewe

Revista Síndrome de Down

Los casos de síndrome de Down debidos a trisomía parcial del cromosoma 21 se dan con una frecuencia muy baja. No por su rareza sino por su particularidad citogenética, estos casos aportan una información muy valiosa para el establecimiento de correlaciones entre el genotipo y el fenotipo. Estudiando el alcance citogenético de cada trisomía parcial y las características clínicas de la persona, se puede determinar qué regiones del cromosoma 21, cuando se encuentran en trisomía, son responsables de una determinada característica clínica. Mediante el estudio detallado de estos casos y estableciendo comparaciones entre ellos, se ha llegado a la construcción de un mapa fenotípico que asigna a las diferentes regiones del cromosoma 21, los diferentes rasgos clínicos del síndrome de Down. Se recoge el estudio citogenético y clínico de seis nuevos casos de síndrome de Down debidos a trisomía parcial del cromosoma 21, para contribuir a la construcción del mapa fenotípico; han permitido, además, ofrecer consejo genético a las familias.CantabriaES

Additional Complexity on Human Chromosome 15q: Identification of a Set of Newly Recognized Duplicons (LCR15) on 15q11–q13, 15q24, and 15q26

Several cytogenetic alterations affect the distal part of the long arm of human chromosome 15, including recurrent rearrangements between 12p13 and 15q25, which cause congenital fibrosarcoma (CFS). We present here the construction of a BAC/PAC contig map that spans 2 Mb from the neurotrophin-3 receptor (NTRK3) gene region on 15q25.3 to the proximal end of the Bloom's syndrome region on 15q26.1, and the identification of a set of new chromosome 15 duplicons. The contig reveals the existence of several regions of sequence similarity with other chromosomes (6q, 7p, and 12p) and with other 15q cytogenetic bands (15q11–q13 and 15q24). One region of similarity maps on 15q11–q13, close to the Prader-Willi/Angelman syndromes (PWS/AS) imprinting center. The 12p similar sequence maps on 12p13, at a distance to the ets variant 6 (ETV6) gene that is equivalent on 15q26.1 to the distance to the NTRK3 gene. These two genes are the targets of the CFS recurrent translocations, suggesting that misalignments between these two chromosomes regions could facilitate recombination. The most striking similarity identified is based on a low copy repeat sequence, mainly present on human chromosome 15 (LCR15), which could be considered a newly recognized duplicon. At least 10 copies of this duplicon are present on chromosome 15, mainly on 15q24 and 15q26. One copy is located close to a HERC2 sequence on the distal end of the PWS/AS region, three around the lysyl oxidase-like (LOXL1) gene on 15q24, and three on 15q26, one of which close to the IQ motif containing GTPase-activating protein 1 (IQGAP1) gene on 15q26.1. These LCR15 span between 13 and 22 kb and contain high identities with the golgin-like protein (GLP) and the SH3 domain-containing protein (SH3P18) gene sequences and have the characteristics of duplicons. Because duplicons flank chromosome regions that are rearranged in human genomic disorders, the LCR15 described here could represent new elements of rearrangements affecting different regions of human chromosome 15q. [The sequence data described in this paper have been submitted to EMBL GenBank with the accession nos. AJ272070, AJ276448, AJ276449, AJ286892-AJ286929, AJ400620, AJ400621, AJ400817-AJ400820, AJ277869AJ277874.